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Amyloids are highly organized protein aggregates that are associated with both neurodegenerative diseases such as
Alzheimer disease and benign functions like skin pigmentation. Amyloids self-polymerize in a nucleation-dependent
manner by recruiting their soluble protein/peptide counterpart and are stable against harsh physical, chemical, and
biochemical conditions. These extraordinary properties make amyloids attractive for applications in nanotechnology.
Here, we suggest the use of amyloids in the formulation of long-acting drugs. It is our rationale that amyloids have the
properties required of a long-acting drug because they are stable depots that guarantee a controlled release of the
active peptide drug from the amyloid termini. This concept is tested with a family of short- and long-acting analogs of
gonadotropin-releasing hormone (GnRH), and it is shown that amyloids thereof can act as a source for the sustained
release of biologically active peptides.
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Introduction
Amyloid ﬁbrils, which are highly organized protein/peptide
aggregates, are the hallmark of amyloid disease [1]. More than
20 human diseases are associated with disease-speciﬁc
protein/peptide aggregation and amyloid ﬁbril formation.
For example, in Parkinson disease, the protein a-synuclein (a-
Syn) and in Alzheimer disease, the amyloid peptide Ab
undergo structural alterations forming amyloid ﬁbrils. These
amyloid ﬁbrils or conformational intermediates thereof are
thought to be the toxic entity of the disease [1]. In striking
contrast to the disease-associated amyloids, there are also
amyloids with beneﬁcial biological activities. For example,
bacteria such as Escherichia coli express extracellular amyloid
ﬁbrils called curli that are involved in surface and cell–cell
contacts promoting community behavior and host coloniza-
tion [2]. The protein of chorion of the eggshell of silkworm is
an amyloid that protects the oocyte and the developing
embryo from a wide range of environmental hazards [3].
Yeast prions do not cause cell death, and are associated with
enhanced survival of the host in certain environmental
conditions [4,5]. The HET-s prion protein of the ﬁlamentous
fungus Podospora anserina forms infectious amyloids that
control a native function called heterokaryon incompatibil-
ity, believed to limit the spread of viral DNA [6]. Further-
more, the human protein Pmel17 forms a functional human
amyloid, which appears to be important in the formation of
skin pigmentation [7]. In light of these functional amyloids
and other evidence, it has been suggested that the disease-
associated amyloid ﬁbrils also have a beneﬁcial function by
sequestering toxic oligomers of the amyloid protein [8].
Since proteins with nonhomologous sequences form
amyloid ﬁbrils, Dobson’s group proposed that under certain
conditions, many proteins and peptides can form amyloid-
like ﬁbrils [9,10], and therefore, the formation of amyloid
ﬁbrils is a generic property of the polypeptide chain [11].
Therefore it is likely that amyloid ﬁbrils share common
properties, and indeed, electron microscopy (EM) studies
suggest that they all form long ﬁlaments of several hundred
nanometers in length and only a few nanometers in diameter
[12]. The ﬁlaments are composed of several protoﬁlaments,
and within a protoﬁlament, hundreds of protein/peptide
molecules are aligned with a cross-b-sheet topology [12,13],
which enables them to bind Congo red (CR) [14] and
Thioﬂavin T (Thio T) [15]. This structural arrangement
makes amyloids inert against harsh treatment such as heat,
pH, proteases, and physical forces. Furthermore, amyloids
grow in a nucleation-dependent manner [16]. The properties
outlined above make amyloids an attractive tool for nano-
technology and bioengineering. For example, amyloids may
be used to make nanowires [17,18], as scaffolds for bioactive
materials [19,20], and as a substrate for neurite outgrowth
and synapse formation, as well as for tissue repair and tissue
engineering [21]. Furthermore, the mechanical properties of
insulin amyloids are comparable with steel [22], indicating the
super stability of amyloid organization. Here, we explore the
use of amyloids in a pharmaceutical application for the
formulation of long-acting drugs. One possibility to make
drugs long acting is their storage in a depot from which the
drug is released slowly in a controlled fashion [23]. It is our
rationale that an amyloid-forming protein/peptide drug has
the necessary properties of a long-acting drug: (1) an amyloid
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PLoS BIOLOGYis a stable reservoir containing only the peptide drug; (2) the
high structural organization of the amyloid aggregate
guarantees a controlled release of the peptide drug from
the ﬁbril termini; and (3) the peptide drug is active upon
release. This concept for drug delivery is in direct contrast to
another approach in which the amyloid propensity of a
peptide is reduced for better solubility and efﬁcacy [24].
We examined the concept of using amyloids for the
formulation of long-acting drugs to a family of analogs of
gonadotropin-releasing hormone (GnRH; p-Glu-His-Trp-Ser-
Tyr-Gly-Leu-Arg-Pro-Gly-NH2). GnRH is produced in the
hypothalamus, stimulates the secretion of gonadotropins, and
thereby plays a major role in the modulation of reproductive
functions [25,26]. GnRH analogs are now recognized as
potential drugs for the management of sex steroid-dependent
pathophysiologies, such as hormone-responsive prostate
cancers, management or treatment of breast and gynecolog-
ical cancers, endometriosis, precocious puberty, uterine
myoma, ovarian hyperandrogenism, premenstrual syndrome,
and the induction of ovulation [26–28]. Most of these
disorders can be treated with long-term applications of
GnRH analogs. However, because GnRH analogs are peptides,
they must be administered subcutaneously on a daily basis,
frequently over long periods of time. Therefore, long-acting
GnRH analogs were developed with a duration of action of up
to 50 d compared to a few hours for normal GnRH [29,30].
Some of these long-acting GnRH analogs exhibit concen-
tration-dependent aggregation and form liquid crystals or
gels in aqueous solution [31,32]. Powell et al. [31] observed
that the addition of electrolyte affects the liquid crystal
stability, as well as the temperature at which birefringent
liquid crystals formed in aqueous formulations of the GnRH
analog deterelix. The GnRH analog leuprolide forms b-sheet–
rich aggregates and gels with increasing peptide concen-
tration or the addition of salts [33], whereas the GnRH
antagonist A-75998 exhibits aggregation and gelation in
aqueous solution [32]. Furthermore, Jiang et al. [34] observed
that subcutaneous injection of a solution containing the
GnRH antagonist orntide forms gel at the injection site at
high doses. Here, we show that gels of long-acting GnRH
analogs are composed of amyloid ﬁbrils and suggest that the
duration of action of GnRH analogs depends on the ability of
the amyloids to slowly release active peptide.
Results
To address the concept that amyloid ﬁbrils can be used for
the formulation of long-acting drugs, we studied the amyloid
formation and some in vivo properties of 23 GnRH analogs,
wild-type GnRH, 11 short-acting analogs, and 11 long-acting
analogs (listed in Tables S1 and S2). The two lists of GnRH
analogs provide information about their amino acid compo-
sition, the half-maximal inhibitory concentration (IC50) for
the receptors, and their duration of action. High-afﬁnity
antagonists have been selected to cover both short- and long-
acting variants, as well as a variety of amino acid sequence
compositions. All analogs were assayed for their capacity to
form amyloids by time-resolved Thio T binding, CR binding,
and EM.
Thio T Binding Differentiates Duration of Action by GnRH
Analogs
The kinetics of ﬁbril formation in vitro is generally a slow
process over several days or weeks, and can be monitored by
the increase of ﬂuorescence intensity of the cross-b-sheet–
sensitive dye, Thio T [15]. Thio T ﬂuorescence is thereby
insigniﬁcant during the initial incubation period of amyloid
aggregation due to the nonexistence of Thio T–sensitive b-
sheet aggregates. After the initial phase, a time-dependent
increase of ﬂuorescence intensity is observed until a
maximum intensity is reached, at which time maximal ﬁbril
formation has occurred. Hence, the Thio T binding study
provides information about the relative rate of the formation
of amyloid ﬁbrils. For the Thio T binding studies, all GnRH
analogs were incubated at room temperature at a concen-
tration of 1 mg/ml in 5% D-mannitol, conditions identical to
the formulation used in the animal experiments [29]. In
addition, 0.01% sodium azide was added. The Thio T
ﬂuorescence was monitored daily for all analogs over a
period of 21 d (Figure 1). With the exception of analog S10,
there is no signiﬁcant Thio T binding by short-acting analogs
during the entire incubation period. In contrast to short-
acting analogs, all long-acting analogs show a signiﬁcant
increase of Thio T intensity indicative of ﬁbril formation.
The long-acting analogs L20 and L23 bind signiﬁcantly more
Thio T during the entire experiment, which suggests that
these analogs form amyloids immediately upon sample
preparation. The Thio T binding studies are summarized in
Figure 1A and 1B: With the exception of S10, all long-acting
analogs produce three to four times more Thio T signal
relative to short-acting analogs after 21 d of incubation,
indicating that duration of action is correlated with amyloid
formation.
CR Binding Supports Amyloid Formation of Long-Acting
GnRH Analogs
To conﬁrm amyloid formation by GnRH analogs, CR
binding was measured. CR, like Thio T, is a dye routinely used
to detect b-sheet–rich assemblies [35]. CR binding can be
measured by the ‘‘red shift’’ change of its absorption
maximum from 490 to 540 nm, by an increase of the dye’s
molar absorptivity, and in favorable cases by eye. All three
types of measurements were performed with GnRH analogs
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Author Summary
Amyloids are highly organized protein aggregates that are
associated with both neurodegenerative diseases such as Alzheimer
disease and benign functions such as skin pigmentation. Amyloids
self-polymerize by recruiting their soluble protein counterpart and
remain stable against harsh physical, chemical, and biochemical
conditions. These extraordinary properties make amyloids attractive
for applications in nanotechnology. Here, we suggest the use of
amyloids in the formulation of long-acting drugs, which are active
over extended periods of days and weeks. Long-acting drugs have
been designed to increase patient comfort, convenience, dosage
accuracy, and assurance of patient compliance for drugs that have a
low oral bioavailability. It is our rationale that amyloids have the
properties required of a long-acting drug because they are stable
depots that guarantee a controlled release of the active peptide
drug from the amyloid termini. This concept is tested with a family
of short- and long-acting analogs of gonadotropin-releasing
hormone, and it is shown that amyloids thereof can act as a source
for the sustained release of biologically active peptides.incubated for 30 d. The data (Figure S1 and Table 1) show
that among 12 of the short-acting analogs, seven do not bind
CR, indicative of no amyloid formation. However, ﬁve short-
acting GnRH analogs, i.e., S3, S4, S6, S10, and S11, bind CR,
showing that some short-acting GnRH-analogs are able to
form amyloids after prolonged incubation (see also below). In
contrast to short-acting analogs, all long-acting analogs bind
CR.
Electron Microscopy Supports the Formation of Amyloid
Fibrils of Long-Acting GnRH Analogs
To formally determine the formation of amyloid ﬁbrils by
GnRH analogs and to characterize other possible assemblies
present in the sample, EM was done on all of the GnRH
analogs. Since the EM analysis is for a qualitative interpre-
tation only, amyloid ﬁbrils and other small aggregates might
be observed under the electron microscope even if only a
minority of the sample forms ﬁbrils. Samples were studied
after 8 and 30 d of incubation. The EM study at day 8 (Figure
2) shows that among 12 short-acting GnRH analogs, only four
(S3, S4, S10, and S11) form amyloid-like ﬁbrils. After day 30,
the EM data suggest that the short-acting analogs S1, S5, S7,
S8, S9, and S12 do not form any detectable amyloid-like
ﬁbrils, but that all other short-acting analogs (i.e., S2, S3, S4,
S6, S10, and S11) form amyloid-like ﬁbrils (Figure S2). In
contrast, all long-acting GnRH-analogs form amyloid-like
ﬁbrils after 8 and 30 d of incubation (Figures 2 and S2). The
ﬁbrils show a wide variety of morphologies, comprising
helical ultrastructures with varying degrees of lateral associ-
ation. Furthermore, the ﬁbrils are composed of one or more
ﬁlaments, resulting in overall diameters ranging from
approximately 6 to 12 nm. No oligomers are observed for
the long-acting compounds at day 8 or at day 30 (Figures 2
and S2). Short worm-like protoﬁbrils are observed only for
L16 at day 8 (Figure 2).
The combination of the Thio T, CR binding, and EM
studies summarized in Table 1 show that all the long-acting
GnRH analogs form amyloid ﬁbrils within a short time
period. Half of the short-acting analogs do not form ﬁbrils
under any of the conditions tested. However, the other half of
the short-acting analogs is able to form ﬁbrils after extended
incubation times and S10 forms ﬁbrils immediately. There-
fore, amyloid ﬁbrils of GnRH analogs appear to be required
but not sufﬁcient for a long-duration of action.
Peptide Release by Amyloid Fibrils of GnRH Analogs
Although amyloid ﬁbrils are very stable, they must follow
thermodynamic equilibrium conditions between ﬁbril and
monomer. The ﬁbril–monomer equilibrium is of particular
importance for the proposed pharmaceutical application,
because ﬁbrils must be both stable enough to guarantee a
long duration of action, and the release of active peptide
must be sufﬁcient to generate effective drug concentrations.
To address these two opposing tasks, peptide release for all
GnRH analogs was measured by a dialysis experiment similar
to a study of the GnRH agonist leuprolide [36]. A total of 200
ll of 30-d-old GnRH analog (in) was dialyzed 4 ml of 5% D-
mannitol (out). A 3.5-kDa cutoff, which is twice the size of the
peptides studied, was chosen to ensure that the released
particles are most likely monomeric. The peptide release and
the remaining aggregates were monitored by ﬂuorescence
over 35 d at room temperature. All but two analogs (i.e., L16
Figure 1. Thio T Binding of GnRH Analogs Indicative of Amyloid Fibril Formation
Thio T fluorescence of (A) short-acting and (B) long-acting analogs listed in Tables 1, S1, and S2 after 21 d of incubation at room temperature without
stirring. Kinetics of fibril formation of (C) short-acting and (D) long-acting GnRH analogs. The intensity of Thio T fluorescence is shown as arbitrary units
(AU). The error bars represent the standard deviation of three independent experiments.
doi:10.1371/journal.pbio.0060017.g001
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cence signal in the emission range of 290–500 nm (excited at
280 nm) and could be analyzed (see Material and Methods for
more details). Figure 3 shows representative examples of the
dialysis experiment displaying normalized ﬂuorescence in-
tensities at wavelength maxima (kmax) both inside (in) and
outside (out) of the membrane. In Figure 3A the monomer
release proﬁle of wild-type GnRH (S12) and the short-acting
analog S1, neither of which form ﬁbrils after 30 d of
incubation (Figures 1 and 2), are shown. The ﬂuorescence
intensities inside and outside of the membrane decrease and
increase, respectively, within a very short period of time and
reach equilibrium within 3 d (Figures 3A and S3). The t1/2 and
Koff of S1 and S12 are approximately 2 d and approximately
4 3 10
 6 S
 1 (Table 1), representing the intrinsic diffusion of
monomeric GnRH analogs through the membrane. Similar
release proﬁles are observed for all of the short-acting
analogs, which do not form ﬁbrils after 30 d of incubation,
as well as the ﬁbril-forming but short-acting analogs S2 and
S6 (Figure 3B) and S11 (Table 1). The latter data suggest that
S2, S6, and S11 form unstable ﬁbrils. In contrast, the release
proﬁles of ﬁbril-forming, but short-acting, analogs S3 and S10
(Figure 3C) and S4 (unpublished data) show very little
ﬂuorescence intensity changes both inside and outside of
the membrane at 35 d. Therefore, the t1/2 and Koff of S3, S4,
and S10 are  35 d and  2310
 7 (Table 1), respectively. The
data suggest that S3, S4, and S10 form very stable amyloids
with very little peptide release. This hypothesis is further
supported by the ﬁnding that S4 is present as amyloid at the
injection site over a period much longer than its duration of
action (see below and Figure S6). It can be concluded that the
release proﬁle of all short-acting analogs indicate that short-
acting analogs are of three categories: (1) not forming ﬁbrils,
(2) forming very unstable ﬁbrils that readily dissociate into
monomers, and (3) forming very stable ﬁbrils such as S4
which release peptides so slowly that an effective concen-
tration of the drug for action eventually is not reached.
In striking contrast, for all the long-acting GnRH analogs, a
gradual decrease in ﬂuorescence intensity inside and a
corresponding increase outside of the membrane is observed
between days 3 and 35 after the initial intrinsic diffusion of
residual monomers within the ﬁrst 3 d (Figure 3D; the
residual monomer comprises thereby only 1%–5% of peptide
as estimated from the relative ﬂuorescence intensities). The
half-life (t1/2) of all long-acting analogs ranges from day 15 to
30 d (Table 1). The Koff of the long-acting analogs (2310
 7 to
7 3 10
 7; Table 1) suggest that long-acting analogs release
monomer approximately ten times faster than short-acting,
very stable, ﬁbril-forming GnRH analogs such as S4.
The Effect of Low Molecular Weight Glycosaminoglycans
on Peptide Release by Amyloid Fibrils of GnRH Analogs
Monomer release in vitro may be altered in vivo by amyloid
binding components from the host, such as amyloid P and
glycosaminoglycans, which may stabilize amyloid ﬁbrils
[37,38]. To test the effect of glycosaminoglycans on ﬁbril
formation and peptide release, the ﬁbril formation and
monomer release proﬁles of samples of compounds L13 and
L14 were measured in absence and presence of low molecular
weight (LMW) heparin (600 lM peptide in 5% D-mannitol,
0.01% sodium azide with or without equimolar LMW
heparin). After overnight incubation in the absence of
LMW heparin, both L13 and L14 samples bind Thio T
indicative of amyloid formation. These data are in line with
earlier experiments (Figures 1 and 2). Interestingly, the
presence of LMW heparin results in much higher Thio T
Table 1. Biochemical and Biophysical Properties of Aggregates By GnRH-Analogs
Hormone Action Thio T
Binding
Congo
Red
EM
8 EM
30 KD
(lM)
t1/2
(day)
Koff
(S
 1)
Correlation
S1 agonist n n nfib nfib ND 2 4 3 10
 6 þ
S2 short n n nfib fib 20 2 4 3 10
 6 þ
S3 short n b fib fib 1.8  35  2 3 10
 7 þ
S4 short n b fib fib 1.1  35  2 3 10
 7 þ
S5 short n n nfib nfib ND 2 4 3 10
 6 þ
S6 short n b nfib fib 26 5 2 3 10
 6 þ
S7 short n n nfib nfib ND 2 4 3 10
 6 þ
S8 very short n n nfib nfib ND 2 4 3 10
 6 þ
S9 very short n n nfib nfib ND 2 4 3 10
 6 þ
S10 short b b fib fib 1.0  35  2 3 10
 7 þ
S11 short n b fib fib 23 3 3 3 10
 6 þ
S12 wt n n nfib nfib ND 2 4 3 10
 6 þ
L13 very long b b fib fib 2 15 5 3 10
 7 þ
L14 long b b fib fib 3 16 5 3 10
 7 þ
L15 long b b fib fib 3 17 5 3 10
 7 þ
L16 long b b fib fib ND ND ND þ
L17 long b b fib fib 5 11.7 7 3 10
 7 þ
L18 long b b fib fib 9 11 7 3 10
 7 þ
L19 long b b fib fib ND ND ND þ
L20 intermediate b b fib fib 8 35 2 3 10
 7 þ
L21 intermediate b b fib fib 2 35 2 3 10
 7 þ
L22 medium b b fib fib 7 28 3 3 10
 7 þ
L23 intermediate b b fib fib 7 30 3 3 10
 7 þ
þ, positive correlation; b, binding; EM
8, electron microscopy at day 8; EM
30, electron microscopy at day 30; fib, fibrils; n, not binding; ND, not determined; nfib, no fibrils; wt, wild type.
doi:10.1371/journal.pbio.0060017.t001
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ﬁndings suggest that LMW heparin induces ﬁbril formation
of peptide analogs L13 and L14. Furthermore, the dialysis
experiment shown in Figure S5 suggests that the presence of
LMW heparin results in the slower release of monomers and a
signiﬁcantly slower decay of the ﬁbrillar material relative to
the control. Therefore, host factors may inﬂuence the in vivo
properties of amyloid ﬁbrils of the GnRH peptide hormone
analogs. In particular, they may stabilize the ﬁbrils.
GnRH Analogs Form Amyloids In Vivo
To determine whether GnRH analogs form and/or stay as
amyloids in vivo at the injection site, we injected them into
adult rats and stained the potential amyloid with CR [39]. A
fresh preparation of the long-acting analog L14 was subcuta-
neously injected at a concentration of 200 lg in 200 llo f5 %
D-mannitol. The sample before injection was in a non-
amyloid state as measured by EM and Thio T binding
(unpublished data). Also 5% D-mannitol was injected as a
control into the same animal. Twenty-four hours after the
subcutaneous injection, the tissues close to the injection sites
were taken for cryo sections, and the tissue sections were
stained with CR. Figure 4 shows that a portion of the tissue is
stained by CR and produces strong birefringence indicating
the presence of amyloid ﬁbrils. No CR binding was observed
with either the control (5% D-mannitol only; unpublished
data) or upon subcutaneous injection of a fresh preparation
of the non-ﬁbrillar short-acting analog S2 (unpublished data).
In contrast, CR binding was observed upon injection of an
aged ﬁbril-containing S2 sample, as well as aged amyloid-
containing or freshly prepared S4 samples. The presence of
amyloids of the S4 sample was observed after 24 h and 7 d of
subcutaneous administration, respectively (Figure S6).
These data show that GnRH analogs are able to form
amyloids in vivo. The capacity of peptide drugs to form
amyloids in vitro has been previously documented for insulin
[40,41] .
The Subcutaneous Administration of Amyloid Fibrils
Prolongs the Duration of Action of the GnRH Analog S2
The correlation between ﬁbril formation and a long
duration of action suggests that a peptide administered in a
ﬁbril form might be longer-acting than in its soluble form if
the latter does not form ﬁbrils immediately upon injection. A
good candidate to test this hypothesis is S2, since it is a short-
acting analog that does not form ﬁbrils upon injection (see
above), but is able to form ﬁbrils in vitro upon long
incubation (Figure S2). Therefore, the duration of action of
a fresh-prepared S2 and an aged ﬁbrillar S2 sample was
measured in vivo with the castrated male rat assay [29]. In
short, 10 d after castration, rats (six per group) were injected
subcutaneously with 50 lg of freshly prepared S2 and aged
ﬁbrillar S2 in 50 ll of 5% mannitol in parallel with a control
(vehicle only). Blood sampling was performed predose, then 1,
6, 24, 48, 72, and 96 h after subcutaneous administration. The
effects of the control and the two S2 samples on the
Figure 2. Morphologies of GnRH Analogs Incubated for 8 d
Transmission electron microscopy (TEM) of negative-stained samples was performed. ‘‘S’’ indicates short-acting and ‘‘L’’ indicates long-acting GnRH
analogs as labeled in Tables 1, S1, and S2. Scale bars indicate 200 nm.
doi:10.1371/journal.pbio.0060017.g002
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Long-Acting Drug Depot by AmyloidsFigure 3. Monomer Release Profiles of GnRH Analogs from Aggregates
Time-dependent monomer release was measured by the intrinsic fluorescence of the GnRH analogs with excitation at 280 nm and emission at the
range of 290–500 nm. The volume- and concentration-corrected fluorescence maxima (Imax) from both inside (in) and outside (out) of the membrane
medium were plotted against time of incubation. The fluorescence intensity is expressed in arbitrary units (AU). A representative set of profiles are
shown: in (A), the monomer release of the short-acting analogs S1 and S12, which do not form fibrils; in (B), the monomer release of short-acting
analogs S2 and S6, which form unstable fibrils; in (C), the monomer release of short-acting analogs S3 and S10, which form very stable fibrils; and in (D),
the monomer release of the long-acting analogs L13 and L15.
doi:10.1371/journal.pbio.0060017.g003
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plasma luteinizing hormone (LH) levels by radioimmunoassay
(Figure 5) [29]. Both samples suppress LH levels in the ﬁrst
24 h as expected [42,43]. However, after 72 h, the freshly
prepared S2 sample lost its action, whereas the aged ﬁbrillar
S2 sample is still highly active in suppression of LH. The loss
of action after 96 h of the ﬁbrillar S2 sample is attributed to
the low stability of the S2 ﬁbrils determined in vitro (Table 1).
Since the only difference between the two S2 samples is the
aggregation state (soluble versus ﬁbrillar), the difference in
the duration of action is therefore due to their different
aggregation state. In conclusion, the formation of ﬁbrils of a
peptide drug can prolong its duration of action.
Toxicity of Amyloids of GnRH Analogs
Since amyloid ﬁbrils can be toxic to cells and are associated
with several neurological diseases [1,44], it is a concern
whether or not amyloid ﬁbrils of GnRH analogs are able to
generate a toxic response as well. To measure the potential
toxicity of GnRH analogs, we used the lactate dehydrogenase
(LDH) release assay for cell killing [44]. The LDH release assay
is a widely used assay to determine the cytotoxicity of
chemicals or environmental toxic factors. LDH is a soluble
cytosolic enzyme that is released into the culture medium
following the loss of membrane integrity. For the LDH assay,
we used mouse embryo ﬁbroblast cells and aged peptide
samples at 60 lM in 5% D-mannitol. Figure 6 shows that in
contrast to the lysate as positive control, neither the peptide
analog samples nor Ab(1–40) generated toxicity in a dermal
cell line. These toxicity studies suggest that amyloid ﬁbrils of
GnRH analogs are not toxic to dermal cells.
Figure 4. In Vivo Amyloid Formation of the GnRH Analog L14
A total of 200 lg of L14 in 200 ll of 5% D-mannitol was injected subcutaneously into an adult rat, which was sacrificed 1 d later. Tissue sections close to
the injection site were stained with CR. In (A) and (B), the red CR staining, and in (C) and (D), the CR birefringence is observed indicative of in vivo
amyloid formation. The pictures of (A) and (B) represent the bright-field microscope images with 53and 103resolutions, respectively. The same section
is shown in (C) and (D) under cross-polarized light with 53 and 103 magnification, respectively.
doi:10.1371/journal.pbio.0060017.g004
Figure 5. The Formation of Fibrils Inhibits LH Release in Castrated Rats
Total dose was 50 lgi n5 0ll (5% mannitol). Blood samples were
collected at the times shown on the abscissa. Results are illustrated as
mean plasma LH levels (n ¼ 6 rats) 6 standard error of the mean (SEM).
Double asterisks (**) indicate p , 0.01 versus vehicle.
doi:10.1371/journal.pbio.0060017.g005
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Analogs
Another concern for the application of amyloids in the
formulation of long-acting drugs is the potential multi-
plication and spread of amyloids through seeding. Only a
small amount of ﬁbrillar seed is needed to induce and
accelerate self-polymerization in the presence of monomeric
amyloid protein/peptide [16]. Within the context of GnRH,
perhaps amyloids of the injected GnRH analogs may act as
the seeds and the host GnRH as the reservoir of the free
monomer. To mimic this situation in vitro, a seeding reaction
was set up with a small amount of matured, long-acting L20
ﬁbrils (5% v/v) in presence of a solution of wild-type GnRH
(95% v/v). The ﬁbril growth of the mixture as well as the wild-
type GnRH alone (S12) and mature L20 ﬁbrils was followed
over a period of 1 mo by Thio T binding (Figure S7A). There
is no signiﬁcant Thio T binding during the entire seeding
experiment, which suggests that L20 ﬁbrils are unable to seed
wild-type GnRH. Further conﬁrmation was obtained by EM at
day 0 and after 1 mo of incubation (Figure S7B). No
detectable amyloid ﬁbrils in the mixture or wild-type GnRH
alone were observed, further supporting the notion that L20
is unable to seed wild-type GnRH.
Although the seeding of amyloids requires a high amino
acid sequence similarity between the protein/peptide of the
seed and its soluble host counterpart [1,45], cross-seeding
between different protein species have been documented [46].
To test whether amyloids of long-acting GnRH analogs are
able to cross-seed with a protein associated with Parkinson
disease, a-Syn, a seeding reaction was done with a small
amount of matured L20 ﬁbrils (5% v/v) in the presence of a-
Syn (95% v/v; 400 lM concentration of monomeric solution
[pH 7.4] in PBS). The ﬁbril growth of the mixture as well as a-
Syn in PBS as control were followed over a period of 30 d by
Thio T binding. As shown in Figure 7, a-Syn aggregates
spontaneously as reported [47]. The addition of a seed of L20
ﬁbrils did not signiﬁcantly inﬂuence the aggregation of a-Syn,
which suggests that the cross-seeding capacity of L20 amyloids
with a-Syn is low. In contrast to the L20 ﬁbril seeding
experiment, the addition of a-Syn ﬁbril seeds accelerated a-
Syn aggregation signiﬁcantly (Figure 7).
Discussion
Drugs of peptide or protein origin usually have low oral or
transdermal bioavailabilities and short in vivo half-life, and
therefore require delivery by infusion, frequent injections, or
subcutaneous administrations. To overcome these delivery
problems, novel formulations of the drugs have been
designed that release continuously over an extended period
to maintain an active drug concentration within the
therapeutic window. Methods for controlled drug release
include implantable devices such as infusion pumps, chips,
Figure 6. Effect on LDH Release by Hormone Fibrils
The mouse embryo fibroblast cells were treated with fibrils of GnRH-analogs, buffer alone (Buffer), and Ab(1–40) (Ab40), and the release of LDH was
assayed. The amount of LDH release is shown as arbitrary units (AU). The cell lysate and Ab(1–40) were used as positive control, whereas cells treated
with buffer alone were used as negative control (black bars). Three independent experiments were performed. ‘‘S’’ indicates short-acting (blue bars)
and ‘‘L’’ indicates long-acting (red bars) GnRH analogs as labeled in Tables 1, S1, and S2.
doi:10.1371/journal.pbio.0060017.g006
Figure 7. Lack of Seeding Capacity of L20 Fibrils on a-Syn
The freshly prepared a-Syn solution in PBS (pH 7.4) was incubated with
5% (v/v) seed of matured L20 amyloid in 5% D-mannitol at 37 8C with
vigorous stirring. a-Syn in PBS (pH 7.4) with 5% (v/v) of 5% D-mannitol
was also incubated as a control. The formation of amyloid was monitored
for the mixture (a-SynþL20; red line), a-Syn in the presence (positive
control; blue line) and the absence (negative control; black line) of a-Syn
seed (5%) by Thio T binding. The intensity of Thio T fluorescence is
shown as arbitrary units (AU) versus time.
doi:10.1371/journal.pbio.0060017.g007
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Long-Acting Drug Depot by Amyloidsand diffusion chambers, as well as biodegradable and easy to
administer hydrogels, liposomes, microspheres, and polymer
depots loaded with the drug of interest [23,48,49]. Another
compelling approach proposed is the crystallization of the
drug followed by the administration of drug crystals, which
serve as a protected reservoir that releases the active
compound relatively slowly [50,51]. Such depot designs may
offer numerous advantages. These include protection of the
drug from enzymatic degradation, the ability to deliver the
drug locally to a particular site in the body, as well as
increased patient comfort, convenience, dosage accuracy, and
assurance of patient compliance [52,53]. However, improved
technologies and new approaches are still needed that can
deliver otherwise insoluble, unstable, or unavailable thera-
peutic compounds to reduce the amount of drugs used, to
release the drug in a ‘‘smart’’ manner, and to maximize the
drug load, which is the amount of drug per depot [54].
Here, we suggest the use of a peptide drug with the ability
to form amyloids before or immediately after administration.
This approach may simultaneously overcome two problems
since the peptide drug itself forms a stable structurally
organized depot, that releases monomeric active peptide
slowly from the amyloid ﬁbril termini (Figure 8). Hence, the
long-acting amyloid drug consists of only one type of
molecule and concomitantly the depot has a drug load of
100%. Another advantage may be that the amyloid ﬁbril
formulation may protect the biological, physical, and
chemical integrity of the drug molecules in the very stable
cross-b-sheet structure during processing, storage, and even
upon delivery. Furthermore, amyloid binding components
from the host organism such as amyloid P and glycosamino-
glycans may stabilize the drug ﬁbrils and protect them from
degradation [37,38,55,56], and may reduce the potential
immune response of the drug by covering the drug ﬁbrils.
In addition, an amyloid drug may be easily administered by
subcutaneous injection, it is highly concentrated since it is
already an aggregate, and the amyloid depot can easily be
located close to the injection site and removed if necessary.
Therefore, an amyloid formulation may allow sustained
release of the peptide drug for a long duration, thus avoiding
the need of repetitive dosing, surgery for implanting depots,
or/and complicated manufacturing procedures for making a
depot ﬁlled with the drug.
To test the concept that amyloid properties of peptides/
proteins may be used for the formulation of long-acting
drugs, we studied GnRH analogs because long-acting GnRH
analogs form gels [29], which is one of the indicators for ﬁbril
formation. Indeed, in vitro analysis of a family of 23 short-
and long-acting analogs shows that all of the long-acting
analogs studied form ﬁbrils that slowly release the peptide
monomer (Table 1). Furthermore, we demonstrated that the
long-acting analogs also have the capacity to form amyloids in
vivo upon subcutaneous injection (Figure 4). In contrast to
long-acting analogs, the short-acting GnRH analogs either do
not form ﬁbrils, form unstable ﬁbrils, which release peptide
quickly, or form very stable ﬁbrils, which do not release
peptide within the period studied (Table 1). In addition, we
show that the administration of a ﬁbrillar sample results in a
longer duration of action than its corresponding soluble
counterpart (Figure 5). The ﬁndings strongly suggest that the
long duration of action is directly related to the ability of the
GnRH analog to form ﬁbrils that release sustained peptide
(Figure 8). The in vitro half-life time of amyloids of GnRH
analogs varies between 2 d to more than 35 d, the Koff varies
more than one order of magnitude as well (Table 1). This
observation also shows that the release of monomer from the
amyloid depot can be controlled by the chemical structure of
the GnRH analog. Concomitantly, the duration of action can
be manipulated through the peptide release property of the
amyloid ﬁbril by the chemical structure of the analog.
Since amyloid ﬁbrils of disease-speciﬁc peptides/proteins
have been associated with a number of diseases, a potential
pitfall of the use of amyloid as storage depot could be
amyloid-associated toxicity of the depot as well as its
potential seeding capacity to amplify amyloids by recruiting
soluble host counterpart, i.e., wild-type GnRH in the context
of this study. Furthermore, the depot might cross-seed other
amyloidogenic proteins. The in vitro seeding experiments
Figure 8. Schematic Representation of the Drug Action by Amyloids of GnRH Analogs
The stable amyloid fibrils formed prior or shortly after subcutaneous injection and gradually release monomeric functional analogs at their termini. The
EM picture shows amyloid fibrils of a long-acting GnRH analog. The end of a fibril is highlighted, and its structural composition of aligned peptides is
schematically indicated. Each peptide colored individually in the fibril schematic interacts with neighboring peptides through intermolecular hydrogen
bonds forming an ‘‘infinite’’ b-sheet along the fibril axis. This structural arrangement requires that peptides can be released only at the termini of the
fibrils, which guarantees a controlled and slow release.
doi:10.1371/journal.pbio.0060017.g008
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neither wild-type GnRH nor a-Syn, a peptide associated with
Parkinson disease (Figures S7 and 7). The rationale of this
lack of seeding is based on the ﬁnding that seeding requires a
host counterpart which has the ability to form ﬁbrils and
comprises a high sequence homology to the amyloid [1,45].
Since, GnRH does not form ﬁbrils (Table 1, S12) and a-Syn
has no signiﬁcant sequence homology with L20, seeding is
unlikely. In addition, the potential capacity of cross-seeding
of the depot in vivo is also unlikely due to the different
compartmental localization of the seed and its host counter-
part, i.e., amyloids of GnRH analogs in the subcutaneous layer
and a-Syn in the brain. The brain and the subcutaneous layer
are additionally separated by the blood–brain barrier,
inhibiting the crossing of peptides to the central nervous
system (CNS). Furthermore, amyloids are not toxic to dermal
cells (Figure 6), and long-acting analogs show good properties
in histamine release [43].
One of the long-acting, amyloid-forming GnRH analogs
under study is degarelix (L13). Its pharmacological proﬁle has
been well studied. Degarelix (L13) has a good safety margin
with regard to histamine release and long duration of action
up to 50 d [30] attributed here to the formation of amyloids.
Degarelix (L13) is in clinical trials for the treatment of
prostate cancer. The results of the Phase IIb clinical trial show
that treatment with degarelix (L13) results in fast, profound,
and sustained reductions in testosterone and prostate-
speciﬁc antigen levels without a testosterone surge. Degarelix
(L13) is currently being tested in Phase III trials [57]. Another
long-acting and amyloid-forming GnRH analog studied here
is ganirelix (L23), which is an approved drug (brand name,
Antagon) for use in assisted reproduction to control
ovulation. Our data suggest that its long duration of action
is also because of its ability to form amyloid ﬁbrils.
Since the formation of amyloid is probably a generic
feature of the polypeptides, the concept of designing peptide/
protein drugs that make amyloid depots for the formulation
of long-acting drugs could be applicable to many drugs of
peptide or protein origin. Primary requirements of this
approach are that monomers that escape from the ﬁbril end
be functional and that a given designed segment, which may
include, if necessary, an amyloidogenic tag, of the peptide/
protein drug forms an amyloid core. The successful applica-
tion to treat human diseases using long-acting, amyloid
forming GnRH analogs such as degarelix and ganirelix
underline the potential of the concept. It follows that in
striking contrast to the original association of amyloids with
diseases, amyloids might also be useful in the treatment of
diseases.
Materials and Methods
Peptide synthesis. Peptides were synthesized using the solid-phase
approach and the Boc strategy as reported earlier [29].
Peptide ﬁbril formation. GnRH analogs were dissolved in a glass
tube in 1 ml of 5% D-mannitol and 0.01% sodium azide at a
concentration of 1 mg/ml. The GnRH analogs were then incubated at
room temperature without stirring. The ﬁbril formation was
monitored by EM, CR, and time-resolved by Thio T binding studies.
Three independent experiments were performed for each sample.
Thio T binding. A 10-ll aliquot of peptide sample was diluted into
500 ll of water with 5% D-mannitol containing 0.01% (w/v) sodium
azide. The solution was mixed with 10 ll of 1 mM Thio T prepared in
the same solution. Fluorescence was measured immediately after
addition of Thio T. The experiment was measured on a spectro-
ﬂuorimeter (Photon Technology International) with excitation at 450
nm and emission at 482 nm. The ﬂuorescence intensity at 482 nm was
plotted against incubation time (day). A rectangular 10-mm quartz
microcuvette was used. Three independent experiments were
performed for each sample.
CR binding. A5 - ll aliquot of peptide sample was mixed with 80 ll
of PBS buffer containing 10% ethanol. Then 15 ll of a 100 lMC R
solution (ﬁltered through 0.2-lm ﬁlter) in PBS containing 10%
ethanol was added. After mixing, UV was measured from 300–700
nm. For the measurement of the CR-only spectrum, 15 llo fC R
solution with 85 ll of PBS containing 10% ethanol was prepared. As a
control, a 5-ll aliquot of GnRH analog mixed with 95 ll of PBS
containing 10% ethanol was measured. Three independent experi-
ments were performed for each sample. In addition to the UV
measurements, pictures of the cuvette containing the peptide sample
and CR were taken to visually show the CR binding to the amyloids.
Electron microscopy. A5 - ll aliquot of peptide sample was diluted
into 50 ll of water to a peptide concentration of approximately 50
lM, spotted on a glow-discharged, carbon-coated Formvar grid
(Electron Microscopy Sciences), incubated for 5 min, washed with
distilled water, and then stained with 1% (w/v) aqueous uranyl
formate solution. Uranyl formate solutions were ﬁltered through 0.2-
lm sterile syringe ﬁlters (Corning) before use. EM analysis was
performed using a JEOL JEM-100CXII electron microscope at 80 kV
with nominal magniﬁcations between 36,000 and 72,000. Images were
recorded digitally by using the SIS Megaview III imaging system. At
least two independent experiments were carried out for each sample.
Effect of LMW heparin on amyloid formation. The 600 lM L13 and
L14 hormone analogs were mixed with 600 lM LMW heparin (5-kDa
heparin from CalBioChem) in 5% D-mannitol, 0.01% sodium azide
(1:1 v/v). The mixtures were incubated overnight. For the control, 600
lM L13 and L14 hormone analogs were also incubated with 5% D-
mannitol (1:1 v/v). The next day, a 10-ll aliquot of peptide sample was
diluted into 500 llo fH 2O with 5% D-mannitol containing 0.01%
(w/v) sodium azide. The solution was mixed with 10 ll of 1 mM Thio T
prepared in the same solution. Fluorescence was measured immedi-
ately after addition of Thio T with a spectroﬂuorimeter (Photon
Technology International) using an excitation wavelength at 450 nm
and emission at 482 nm. The ﬂuorescence intensity at 482 nm was
plotted. Three independent experiments were performed for each
sample.
Peptide release from amyloid. A 200-ll aliquot of aged GnRH in
solution conditions given above was transferred into a 0.6-ml
Eppendorf tube with a hole in the cap. To study the effect of heparin
on peptide release, a mixture of hormone analog and heparin (1:1 v/v)
was incubated overnight in parallel with a half-diluted peptide ﬁbril
sample in 5% D-mannitol and 0.01% sodium azide. The hole in the
cap of the Eppendorf tube was sealed with a 3.5-kDa molecular weight
cutoff (MWCO) membrane. Next, the Eppendorf tube was inserted
upside down into a 15-ml Falcon tube containing 4 ml of 5% D-
mannitol in water and 0.01% sodium azide. Care was taken to make
sure that the membrane was exposed to solutions both in and outside
and that any bubbles at the membrane interface were removed. The
tubes were then incubated at room temperature. To measure the
remaining peptide concentration inside the 0.6-ml Eppendorf tube, a
5-ll aliquot was diluted into 500 ll water with 5% D-mannitol, 0.01%
sodium azide, and the ﬂuorescence was measured with excitation at
280 nm and emission in the range of 290–500 nm. The excitation slit
width was 2 nm, and emission slit width was 11 nm. To determine the
peptide concentration outside the membrane in the 15-ml tube, an
aliquot of 250 ll of solution was taken from the releasing medium,
diluted into 500 ll ﬁnal volume by 5% D-mannitol, 0.01% sodium
azide, and ﬂuorescence was measured. Following spectra recording,
the dialysis system was reassembled as described above. No signiﬁcant
change (65 nm) of the wavelength maxima (kmax) of the ﬂuorescence
spectra from solutions inside and outside of the membrane was
observed. Furthermore, an independent experiment, in which the
intrinsic ﬂuorescence during aggregation of GnRH analogs was
measured over a period of 30 d, did not show signiﬁcant changes of
ﬂuorescence intensity and wavelength maxima from freshly prepared
solution to aggregates by 30 d of incubation (unpublished data). The
normalized intensity maxima from inside and outside the membrane
were plotted as a function of time and ﬁt by an exponential function
to extract the half-life of the ﬁbrils and the Koff, respectively. The
data from day 0 and day 1 of incubation were not used in the analysis,
because loosely bound monomer or monomers that are already in
equilibrium with ﬁbrils pass through the membrane during this initial
incubation period, resulting in a bi-exponential function, which is
difﬁcult to ﬁt. The extracted half-life, t1/2, is the time taken, during
which the ﬂuorescence signal inside the 0.6-ml Eppendorf tube drops
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equal to the ﬁnal monomer concentration in accordance to
O’Nuallain et al. [58].
In vivo rat experiments. Skin harvest: Adult male Sprague-Dawley
rats (180–220 g) were injected subcutaneously in shaved areas with
the vehicle, freshly prepared (i.e., L14, S2, S4, and vehicle-only; 200
lg/200 ll at four sites/rat), or aged GnRH analogs (i.e., S2 and S4; 200
lg/200 ll at one site/rat). Twenty-four hours or 7 d later, the animals
were deeply anesthetized and tissues, including skin and muscle
around the injection sites, were collected. They were then ﬁxed in
fresh 4% paraformaldehyde for 7 d, postﬁxed in 20% sucrose/4%
PFA overnight, and divided into three sections per treatment. Each
section was cut on cryostat at 10-lm thickness and stained with CR.
LH levels: Adult male Sprague-Dawley rats (180–200 g were
castrated under isoﬂurane anesthesia 10 d prior to the start of the
experiment, and implanted with indwelling jugular cannulae 48 h
prior to the assay for serial blood sampling [59]. The peptides (200 lg)
were dissolved either fresh in 200 ll of bacteriostatic water
containing 5% mannitol or aged under the same conditions for 4
mo. The rats were injected subcutaneous with a total dose of 50 ll.
Controls received the vehicle. Plasma LH levels were determined by
radioimmunoassay (RIA) using reagents provided by the National
Pituitary and Hormone Distribution Program of the National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK;
Bethesda, Maryland) [60]. All protocols were approved by the Salk
Institute’s Institutional Animal Care and Use Committee (IACUC).
In-cell CR birefringence. The CR staining was performed using the
diagnostic amyloidal stain kit HT60 from Sigma. Brieﬂy, microscopic
slides containing tissue were stained with hematoxylin solution (Gill
No. 3) for 10 min and rinsed in tap water for 5 min. Slides were
placed in alkaline sodium chloride solution for 20 min and
subsequently stained in alkaline CR solution for 20 min. The slides
were rinsed three times with absolute ethanol and cleared in xylene
before mounting. The samples were analyzed using a microscope
equipped with a dual polarizer and a charge-coupled device (CCD)
camera.
LDH release assay. For the LDH assay, we used mouse embryo
ﬁbroblast cells and peptide ﬁbrils at 60 lM ﬁnal concentration in 5%
D-mannitol. For the buffer control, we used 5% D-mannitol in water.
We also used 1 lMA b(1–40) and a cell lysate to compare our data.
The assay was done using a kit (Sigma) as described by the
manufacturer. The assays were done in triplicate and the data
presented as the standard error of the mean.
Seeding experiment. A total of 5 ll of matured L20 ﬁbril solution
at a concentration of 1 mg/ml in 5% D-mannitol, 0.01% sodium
azide was mixed with 95 ll of freshly prepared GnRH solution in the
same solution condition followed by incubation at room temper-
ature without stirring. At day 0 and day 30, aliquots of the mixture as
well as the original solution were taken for EM. Once a week, a 10-ll
aliquot was diluted into 500 ll water containing 5% D-mannitol,
0.01% sodium azide, and 10 ll of 1 mM Thio T to measure the Thio
T ﬂuorescence as described above. Wild-type a-Syn was expressed
and puriﬁed according to Kessler et al. [47]. Solid r-Syn was
dissolved in PBS (pH 7.4), 0.01% sodium azide at a concentration of
10 mg/ml. The pH was adjusted to 7.4 by adding the appropriate
amount of NaOH solution. The solution was brieﬂy vortexed and
then transferred to ﬁlters (50,000 MWCO, Microcon YM-50;
Millipore), and centrifuged for 30 min at 16,000g using a benchtop
microcentrifuge (Eppendorf model 5417R; Brinkmann Instruments).
The cutoff ﬁlters were washed three times by centrifuging with 200 ll
of PBS (pH 7.4) before use. The resulting solution should contain
only monomer or dimer wild-type a-Syn. The protein concentration
of the supernatant was measured by UV absorbance with e280 of
6,500 M
 1cm
 1. The 400 lM a-Syn solution was incubated with 5%
(v/v) seed of matured L20 amyloid in 5% D-mannitol at 37 8C with
vigorous stirring. a-Syn with only 5% D-mannitol was also incubated
as a control. The monomeric solution of a-Syn was incubated with
5% (v/v) of sonicated a-Syn ﬁbril seed as a positive seeding control.
The formation of amyloid was monitored regularly for the mixture
(a-SynþL20) and a-Syn by Thio T binding.
Supporting Information
Figure S1. CR Binding of GnRH Analogs Incubated for 30 d
The GnRH analogs are labeled in accordance to Tables 1, S1, and S2.
Pictures of a 10-mm ﬂuorescence cuvette containing the peptide
sample upon CR binding were taken to show visually the CR binding
to the amyloids. ‘‘C’’ indicates control of only CR solution.
Found at doi:10.1371/journal.pbio.0060017.sg001 (285 KB PDF).
Figure S2. Morphologies of GnRH Analogs Incubated for 30 d
Transmission electron microscopy (TEM) was performed on negative-
stained samples. The GnRH analogs are labeled in accordance to
Tables 1, S1, and S2. Scale bars indicate 200 nm.
Found at doi:10.1371/journal.pbio.0060017.sg002 (284 KB PDF).
Figure S3. In Vitro Release Proﬁles of GnRH Analogs from
Aggregates
As a supplement to Figure 3, the ﬂuorescence spectra and the release
proﬁles of S1, S2, S3, and L15 are shown. The ﬂuorescence spectra
were measured with excitation at 280 nm and emission at the range of
290–500 nm at day 0, 1, 3, 17, and 35 as indicated. The nomenclature
described in Figure 3 is used.
Found at doi:10.1371/journal.pbio.0060017.sg003 (307 KB PDF).
Figure S4. Thio T Binding of GnRH Analogs in Presence and Absence
of LMW Heparin
Thio T ﬂuorescence of L13 and L14 after overnight incubation in
presence or absence of LMW heparin are presented. The intensity of
Thio T ﬂuorescence is shown as arbitrary units (AU).
Found at doi:10.1371/journal.pbio.0060017.sg004 (41 KB PDF).
Figure S5. Effect of LMW Heparin on Monomer Release Proﬁles of
Long-Acting GnRH Analogs
Time-dependent monomer release of aged samples of L14 in absence
(control) and in presence of LMW heparin was measured by the
intrinsic ﬂuorescence of the GnRH analogs with excitation at 280 nm
and emission at the range of 290–500 nm. The volume and
concentration corrected ﬂuorescence maxima (Imax) from both inside
(in) and outside (out) of the membrane medium were plotted against
time of incubation. The same terminology as in Figure 3 is used. The
labels ‘‘Hep-in’’ and ‘‘Hep-out’’ are the corresponding labels of the
experiment in presence of LMW heparin. The ﬂuorescence intensity
is expressed in arbitrary units (AU).
Found at doi:10.1371/journal.pbio.0060017.sg005 (27 KB PDF).
Figure S6. In Vivo Amyloid Formation of Short-Acting GnRH
Analogs
The monomer and ﬁbrils preparations of S2 and S4 (200 lg/200 ll) in
5% D-mannitol, 0.01% sodium azide were injected subcutaneously
into 2-mo-old rats, which were sacriﬁced 1 d and 7 d later,
respectively. Tissue sections close to the injection site were stained
with CR. The pictures on the left side represent the bright-ﬁeld
microscope images with 103 resolutions. The same sections are
shown on the right side under cross-polarized light with 103
magniﬁcation.
(A) Tissue section harvested 24 h upon injection with an aged S2
sample that shows amyloid ﬁbrils under the microscope (unpublished
data).
(B) Corresponding tissue section upon injection of freshly prepared
S4 representing monomeric S4.
(C) Corresponding tissue section upon injection of an aged S4
sample, which shows amyloid ﬁbrils under the microscope.
(D) and (E) Tissue sections harvested after 7 d upon injection of an
aliquot of the same fresh and aged S4 samples used in (B) and (C).
Found at doi:10.1371/journal.pbio.0060017.sg006 (724 KB PDF).
Figure S7. Lack of Seeding Capacity of L20 Fibrils on Wild-Type
GnRH (S12)
GnRH (S12) was incubated with a seed of matured L20 amyloids (5%
v/v) at room temperature for 1 mo in 5% D-mannitol, 0.01% sodium
azide, without stirring. The formation of amyloid was monitored for
the mixture (L20þS12), matured L20, as well as S12 only by (A) Thio T
binding in a time-resolved manner and by (B) EM at day 0 and day 30.
(A) The intensity of Thio T ﬂuorescence is shown as arbitrary units
(AU) versus time.
(B) Scale bars indicate 200 nm.
Found at doi:10.1371/journal.pbio.0060017.sg007 (248 KB PDF).
Table S1. Short-Acting GnRH Analogs with Their Duration of Action
Found at doi:10.1371/journal.pbio.0060017.st001 (85 KB DOC).
Table S2. Long-Acting GnRH Analogs with Their Duration of Action
Found at doi:10.1371/journal.pbio.0060017.st002 (82 KB PDF).
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